During the last 10 years, numerous soft tissue augmentation materials have been developed for correction and filling of photoaging-related facial lines and wrinkles. These novel materials, which are most often used for perioral and glabellar rhytides, have usually been injectable pastelike liquids that can be propelled directly and with minimal risk and discomfort into the skin or subcutis using a needle and syringe apparatus. Intuitively, achieving camouflage by extruding a line of substance into a skin furrow is analogous to using moldable putty to smooth a depression.
SHORT-ACTING, MEDIUM-TERM, AND PERMANENT INJECTABLE TISSUE AUGMENTATION MATERIALS
The pace of change is accelerating, particularly in regard to the Food and Drug Administration (FDA) approval process. For the past 20 years, the only commonly used FDA-approved injectable filler was bovine collagen (eg, Zyderm I and II and Zyplast).1 Then, during the past 24 months, the FDA sanctioned 3 hyaluronic acid products (ie, Restylane, Hylaform, and Captique),2-3 approved an injectable fibroplasia-inducing agent . . . [Full Text of this Article]
SAFETY STUDIES OF INJECTABLE SOFT TISSUE AUGMENTATION MATERIALS
THE CASE OF SILICONE BREAST IMPLANTS: GUIDANCE FOR THE MANAGEMENT OF INJECTABLE AUGMENTATION MATERIALS
History of Silicone Breast Implant Use and Government Regulation
Major Epidemiologic Investigations of the Association Between Breast Implants and Connective Tissue Disease
Meta-Analyses and Consensus Statements Regarding the Association Between Breast Implants and Connective Tissue Disease
Assessment of the Link Between Breast Implants and Connective Tissue Disease Using Criteria for Causality
Was the FDA’s 1992 Policy on Silicone Breast Implants Justified?
RELEVANCE OF THE BREAST IMPLANT DEBATE TO PERMANENT INJECTABLE SOFT TISSUE AUGMENTATION OF THE FACE
RECOMMENDATIONS FOR THE USE OF NOVEL INJECTABLE SOFT TISSUE AUGMENTATION MATERIALS
AUTHOR INFORMATION
